Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Innovotech Inc.: First-Ever Test Helps In Fight Against Serious Lung Infections And Opens Door For Treating Other Life-Threatening Infections
A new test developed by Edmonton-based Innovotech Inc. (TSX VENTURE:IOT) will now allow doctors to more accurately identify the right antibiotics required to treat serious, chronic infections that are biofilm based. With more than 80 per cent of infections in the developed world caused by biofilms, the potential for this new breakthrough test, called bioFILM PATM, is of immense significance to the medical community.
generic viagra online
Leading NGOS Call For International Action To Combat Epidemic Of Non-Communicable Diseases
The International Diabetes Federation (IDF), International Union Against Cancer (UICC) and World Heart Federation (WHF) issued a joint statement that calls on the international community to address urgently the epidemic of non-communicable diseases (NCDs), responsible for 35 million deaths a year. The statement demands a substantial increase in funding for NCDs and greater availability of essential medicines, among other urgent responses, in a way to accelerate achievement of the health Millennium Development Goals.
News of the day
New Jersey Senate, Assembly Panels Advance Autism Coverage Bill
Committees in the New Jersey Senate and Assembly on Monday unanimously approved a bill that would provide insurance benefits of up to $36,000 annually for autism treatments, the Philadelphia Inquirer reports. The funding, provided to developmentally disabled individuals younger than age 21, would go toward diagnostic services and early behavioral intervention, as well as occupational, physical and speech therapies. The Assembly could vote on the bill as early as Thursday, while the Senate bill is being considered by the state Senate Budget and Appropriations Committee.Sen. Loretta Weinberg (D), who sponsored the Senate bill, said, "I don"t know of any parent who wouldn"t do everything in their power to give their autistic or developmentally disabled child every chance to excel. However, the enormous cost of behavior intervention ... makes it out of the realm of possibility for many families." Assembly Speaker Joseph Roberts (D), who sponsored the Assembly bill, said, "In this economy, every New Jersey resident is struggling, but families with kids with special needs are struggling even more," adding, "They"re maxing out their credit cards and taking out second mortgages" to cover gaps in health insurance benefits.Citing cost issues, the New Jersey Business and Industry Association and the New Jersey Association of Health Plans were among those opposed to the bill. Christine Stearns, NJBIA vice president for health and legal affairs, said that the bill would make employer-sponsored insurance more costly and cause firms to drop such coverage, adding, "How, who and what is part of a basic health plan is all part of that." Stearns added that the bill is preferable to previous versions because it mandates that covered services be medically necessary and prescribed, places a reasonable cap on prices and ensures that the cost of educational services provided by schools is not shifted to insurers. Roberts said the bill would save money by delivering earlier treatment that could prevent more costly problems in the future (Henry, Philadelphia Inquirer, 5/19).
Cardiovascular

Stem Cell Therapeutics Corp. Announces The FDA Has Lifted Its Clinical Hold On The Phase IIb Stroke Trial

Stem Cell Therapeutics Corp. ("SCT" or "the Company") (TSX VENTURE:SSS) is pleased to announce the U.S. Food and Drug Administration ("FDA") has provided a verbal confirmation to remove its clinical hold placed on NTx®-265 on September 18, 2008. This will allow SCT to commence the recruitment of patients under an amended protocol using NTx®-265 for the Company"s Phase IIb clinical trial treating acute ischemic stroke. Dr. Alan Moore, President and CEO, commented as follows: "We are very pleased that our series of collaborative meetings with the FDA has resulted in this positive development. We are expecting to receive written notification from the FDA in the near future following which we will finalize the plans for our stroke trial. We will issue another press release once this has been determined." About REGENESIS NTx®-265 is SCT"s lead therapeutic regimen of two approved and clinically well-defined drugs, human Chorionic Gonadotropin ("hCG") and Erythropoietin ("EPO"), targeting the treatment of stroke. The twin objectives of the treatment are to stimulate the growth and differentiation of new neurons to replace the brain cells that were lost or damaged by the stroke, and importantly, to direct motor, visual, and cognitive recovery after the acute ischemic stroke. Encouraging clinical results from SCT"s BETAS Phase IIa stroke trial were presented at the International Stroke Conference in February 2009, showing clinically relevant recovery in 12 of 12 patients who received the complete treatment. Stem Cell Therapeutics Corp.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009